<DOC>
	<DOCNO>NCT03069365</DOCNO>
	<brief_summary>This Phase 3b , open-label , non-randomized study evaluate efficacy safety Glecaprevir/Pibrentasvir ( GLE/PIB ) 8 , 12 , 16 week participant chronic hepatitis C virus ( HCV ) genotype ( GT ) 1 - 6 infection without compensate liver cirrhosis chronic renal impairment HCV treatment-naïve prior treatment-experienced participant .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Glecaprevir/Pibrentasvir Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>Participant positive antihepatitis C virus ( HCV ) antibody ( Ab ) plasma HCV ribonucleic acid ( RNA ) great equal 1000 IU/mL Screening Visit . Participant estimate glomerular filtration rate ( eGFR ) less 45mL/min/1.73 m^2 Cirrhotic participant : absence hepatocellular carcinoma ( HCC ) Current HBV human immunodeficiency virus ( HIV ) infection screen test , define : Positive test result screen hepatitis B surface antigen ( HBsAg ) HBV DNA less low limit quantification ( LLOQ ) participant isolate positive antiHBc ( i.e. , negative HBsAg AntiHBs ) , Positive antiHIV antibody ( Ab ) . Clinical history acute renal failure 3 month prior screen . Clinically significant abnormality comorbidities , recent ( within 6 month prior study drug administration ) alcohol drug abuse could preclude adherence protocol opinion investigator . Receipt investigational commercially available direct act antiHCV agent sofosbuvir .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ribavirin ( RBV )</keyword>
	<keyword>non-cirrhotic</keyword>
	<keyword>treatment naïve</keyword>
	<keyword>interferon ( IFN )</keyword>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Hepatitis C Virus Genotype</keyword>
	<keyword>Chronic Hepatitis C Virus</keyword>
	<keyword>compensate cirrhosis</keyword>
	<keyword>pegylated interferon ( pegIFN )</keyword>
	<keyword>sofosbuvir ( SOF )</keyword>
	<keyword>Glecaprevir</keyword>
	<keyword>Pibrentasvir</keyword>
</DOC>